Australia's most trusted
source of pharma news
Sunday, 14 December 2025
Posted 27 May 2025 AM
CSL Seqirus has successfully opposed a patent filed by Moderna that covers a delivery system for its mRNA vaccines.
It's a blow for the mRNA giant, which would be keen to extend exclusivity for the formulation, but one which it may be able to rectify.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.